Wyeth

Pfizer Corporation

Boston Medical Center Corporation

Stephen Berasi

Zong Sean Juo

Robert Vincent Martinez

John Martin Wozney

Howard Seeherman

Christopher Todd Brown

Valerie Calabro

Michael John Cain

Nathan Higginson-Scott

Stefano V Gulla

Sreekumar R Kodangattil

Janet Elizabeth Buhlmann

David J Salant

Weining Lu

Xueping Fan

Christine Huard

Michael Shamashkin

Matthew Russo

Ruth E Gimeno

Eric M Bennett

Janet E Paulsen

Huilan Gao

Eugene Lee Brown

Jian Li

Z Sean Juo

Dongmei Li

Heather Shih

Ying Sun

The invention provides recombinant Roundabout Receptor 2 (ROBO2) proteins designed to bind SLIT ligands and prevent their binding to ROBO2 cell surface receptors. Also provided are methods for use of these recombinant ROBO2 proteins.

Recombinant ROBO2 proteins, compositions, methods and uses thereof

The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ROBO2, as well as uses, and methods thereof.

Anti-ROBO2 antibodies, compositions, methods and uses thereof

The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.

Designer osteogenic proteins

Osteogenic proteins

The present invention provides methods of affecting gluconeogenesis by altering the levels or activity of DUSP4 and/or EGR1. Pharmaceutical compositions comprising or encoding modulators of gluconeogenesis are also disclosed.

Modulators of gluconeogenesis

Growing community of inventors

Arlington, MA, United States of America

Stephen Berasi